APA (7th ed.) Citation

Chen, Z., Chueh, C., Chiang, N., & Tsai, Y. (2023). Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: From the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration. Cost Effectiveness & Resource Allocation, 21(1), 1. https://doi.org/10.1186/s12962-023-00473-5

Chicago Style (17th ed.) Citation

Chen, Zi-Rong, Chen-Han Chueh, Nai-Jung Chiang, and Yi-Wen Tsai. "Cost-effectiveness of Pemigatinib as a Second-line Treatment for Advanced Intrahepatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions in Taiwan: From the Evidence of the Phase II Trial and the Perspective of Taiwan's National Health Insurance Administration." Cost Effectiveness & Resource Allocation 21, no. 1 (2023): 1. https://doi.org/10.1186/s12962-023-00473-5.

MLA (9th ed.) Citation

Chen, Zi-Rong, et al. "Cost-effectiveness of Pemigatinib as a Second-line Treatment for Advanced Intrahepatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions in Taiwan: From the Evidence of the Phase II Trial and the Perspective of Taiwan's National Health Insurance Administration." Cost Effectiveness & Resource Allocation, vol. 21, no. 1, 2023, p. 1, https://doi.org/10.1186/s12962-023-00473-5.